DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20175096

Emergence of resistance to linezolid in methicillin resistant Staphylococcus haemolyticus reported from the sub Himalayan region of India

Divya Chauhan, Santwana Verma, Ravi Verma, Garima Sharma

Abstract


The spread of resistance among coagulase negative Staphylococci against major drugs is alarming as it limits the treatment options for serious infections. Resistance to linezolid in these organisms is emerging and further compounded by being observed in multidrug resistant strains. It is the only antibiotic available as an oral formulation for resistant Staphylococcal infections and due to the presence of a novel structure and unique mechanism of action, it does not display cross resistance with other classes of antimicrobial agents. However, the widespread use of Linezolid has gradually turned the impending fear of emergence of resistance against this novel drug into a reality. Herein we report a case of sepsis due to methicillin resistant Staphylococcus haemolyticus in a 16-year-old male child found resistant to linezolid, rarely reported from Sub Himalayan region of Indian sub-continent.


Keywords


Methicillin resistant Staphylococcus haemolyticus, Linezolid resistance

Full Text:

PDF

References


Mac Dougall C, Chambers H. Protein synthesis inhibitors and miscellaneous antibacterial agents. In Goodman and Gilman’s, the pharmacological basis of therapeutics. McGraw-Hill, New York. 2011;12:1521-47.

Wennersten C, Venkataraman L. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-8.

Kelly S, Collins J, Maguire M. An outbreak of colonization with linezolid resistant Staphylococcus epidermidis in an intensive therapy unit. J Anti Chemother. 2008;61:9017.

Trevino M, Martinez-Lamas L, Romero-Jung PA. Endemic linezolid resistant Staphylococcus epidermidis in a critical care unit. Eur J Clin Microbiol Infect Dis. 2009;28:527-33.

CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement

M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.

Peer MA, Nasir RA, Kakru DK, Fomda BA, Bashir G, Sheikh IA. Sepsis due to linezolid resistant Staphylococcus cohnii and Staphylococcus kloosii: First reports of linezolid resistance in coagulase-negative Staphylococci from India. Indian J Med Microbiol. 2011;29:60-2.

Kalawat.U, Sharma KK, Reddy S. Linezolid-resistant Staphylococcus spp. at a tertiary care hospital of Andhra Pradesh. Indian J Med Microbiol. 2011;29(3):314-5.

FlauhatS, Vinogradov E, Kelly KA, Brenan S, Hiramatsu K, Lee JC. Structural and Biological Characterization of a Capsular Polysaccharide produced by Staphylococcus haemolyticus J Bacteriol. 2008:190:1649-57.

Linezolid resistant mucoid Staphylococcus haemolyticus from a tertiary care centre in Delhi. New Microbe and New Infect. 2016;11:57-8.

Gupta V, Garg S, Jain R, Garg S, Chander J. Linezolid resistant Staphylococcus haemolyticus: First case report from India. Asia Pacific J Tropic Medic. 2012:837-8.

Anderegg TR, Sader HS, Fritsche TR. Trends in linezolid susceptibility patterns: Report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents. 2005;26:13-21.

De Almeida LM, De Paula AI, Guimarães T, Pavez M, Sacramento AG, Lemos LC, et al. Linezolid‐resistant S. epidermidis clone ST‐2 isolated from a patient who did not receive any course of oxazolidinone therapy: a case report. JMM Case Reports. 2014;1(3).

Gandham P. Linezolid resistant Staphylococcus aureus. Int J Res Med Sci. 2014;2(4):1253-6.